H Antibody

What experimental methods are used to quantify H antibodies in clinical samples?

H antibody quantification relies on immunoassays such as enzyme-linked immunosorbent assay (ELISA) and functional inhibition tests. For Helicobacter pylori IgG detection, ELISA measures antibody titers against bacterial antigens like urease or CagA, with thresholds calibrated to minimize cross-reactivity . In autoimmune anti-factor H antibody studies, titers >150 AU/mL at 1:50 dilution are diagnostic for atypical hemolytic uremic syndrome (aHUS), validated via serial dilutions and standardized controls .

For influenza hemagglutinin (HA) stalk antibodies, inhibition ELISAs assess binding interference with monoclonal antibodies (e.g., CR6261, C179), correlating polyclonal responses with neutralization potential . A critical step is normalizing optical density (OD) values against negative controls to calculate percent inhibition:
$\text{Inhibition (\%)} = 100 - \left( \frac{\text{OD}_{\text{sample}}}{\text{OD}_{\text{control}}} \times 100 \right)$ .

How do H antibody titers correlate with disease progression or protection?

Longitudinal studies in aHUS patients demonstrate that elevated anti-factor H antibody titers (>10,000 AU/mL) predict relapse risk, with hazard ratios of 3.2 (95% CI: 1.8–5.7) after immunosuppression withdrawal . In influenza, baseline anti-HA stalk titers ≥1:160 reduce viral shedding duration by 1.8 days (ρ = -0.34, P < 0.01), though they do not mitigate symptom severity .

Table 1: Correlation Between Antibody Titers and Clinical Outcomes

How can researchers resolve contradictions in H antibody functional data?

Conflicting results often arise from assay variability or epitope heterogeneity. For example, anti-factor H antibodies in aHUS predominantly target SCR 17–20 domains, but cross-reactivity with SCR 5–8 occurs in 25% of patients, complicating functional assays . To address this:

• Epitope Mapping: Use recombinant FH fragments (e.g., SCR 1–4, 5–8) in competitive ELISAs to identify binding regions .

• Functional Validation: Pair ELISA with sheep red blood cell (SRBC) lysis assays to confirm complement dysregulation .

• Multivariate Analysis: Apply generalized estimating equations (GEE) to distinguish antibody titer effects from confounding variables like genetic polymorphisms .

How should researchers interpret anti-H antibody cross-reactivity in multiplex assays?

Cross-reactivity is a major confounder in serological studies. In H. pylori diagnostics, 15% of false positives arise from antigenic mimicry with commensal gut bacteria . Mitigation strategies include:

• Absorption Testing: Pre-incubate sera with E. coli lysates to remove non-specific antibodies .

• Multiplex Bead Assays: Use Luminex platforms to measure reactivity against 10+ antigens simultaneously, improving specificity to 92% .

For anti-HA stalk antibodies, inhibition ELISAs with monoclonal competitors (e.g., 70-1F02) differentiate broadly neutralizing antibodies from non-functional binders .

What biomarkers complement H antibody titers in predicting therapeutic response?

In aHUS, free factor H levels inversely correlate with antibody titers (r = -0.62, P < 0.001) and predict relapse within 6 months (AUC = 0.81) . In influenza, combining anti-HA stalk titers with neuraminidase inhibition (NAI) titers improves prediction of symptom severity (ΔAUC = +0.12) .

Table 2: Biomarker Panels for H Antibody-Associated Diseases